More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$62.37B
EPS
2.36
P/E ratio
17.3
Price to sales
2.95
Dividend yield
--
Beta
0.601956
Previous close
$43.69
Today's open
$43.28
Day's range
$43.02 - $43.83
52 week range
$39.57 - $102.71
show more
CEO
Michael F. Mahoney
Employees
59000
Headquarters
Marlborough, MA
Exchange
New York Stock Exchange
Shares outstanding
1.45B
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation - BSX
NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
GlobeNewsWire • Nov 17, 2026

Should You Book Profits or Hold BSX Stock Post-Q3 Earnings?
Boston Scientific BSX saw modest sales growth in the third quarter, with revenues climbing 1.5% year over year to $5.14 billion, though its adjusted earnings per share (“EPS”) dipped 2.7% to 73 cents year over year. Primarily due to unexpected headwinds within two high-growth franchises, WATCHMAN and Electrophysiology (“EP”), the company lowered its expectations for the rest of the year.
Zacks Investment Research • Nov 16, 2026

Bear of the Day: Boston Scientific (BSX)
I last wrote about Boston Scientific ( BSX ) as the Bear of the Day in early August after their Q2 report and management's lowered guidance propelled analysts to notch down their EPS estimates for this year and next, causing BSX shares to fall into the cellar of the Zacks Rank.
Zacks Investment Research • Nov 13, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation - BSX
NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
PRNewsWire • Nov 12, 2026

Boston Scientific Bets on WATCHMAN Growth Despite Market Slowdown
BSX bets on WATCHMAN growth through clinical trials and physician outreach, even as slowing demand and rising competition cloud its outlook.
Zacks Investment Research • Nov 12, 2026

Boston Scientific Targets Long-Term Growth as Key Businesses Face Pressure Through 2027
Boston Scientific NYSE: BSX executives said they expect durable growth across the company's interventional portfolio, while acknowledging that its pulsed field ablation and WATCHMAN businesses face competitive challenges through 2027.
MarketBeat • Nov 11, 2026

Boston Scientific Corporation (BSX) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
Boston Scientific Corporation (BSX) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
Seeking Alpha • Nov 11, 2026

Wall Street Analysts Look Bullish on Boston Scientific (BSX): Should You Buy?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Zacks Investment Research • Nov 10, 2026

BOSTON SCIENTIFIC CORPORATION INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Boston Scientific Corporation's Directors and Officers for Breach of Fiduciary Duties – BSX
NEW YORK--(BUSINESS WIRE)---- $BSX #NYSE--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of Boston Scientific Corporation (NYSE: BSX) failed to manage Boston Scientific in an acceptable manner, breaching their fiduciary duties to Boston Scientific, and whether Boston Scientific and its shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know: On February 4, 2026, B.
Business Wire • Nov 5, 2026

Here is What to Know Beyond Why Boston Scientific Corporation (BSX) is a Trending Stock
Boston Scientific (BSX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Zacks Investment Research • Nov 5, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Boston Scientific Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.